FIGO Ovarian Cancer Staging Effective Jan. 1, 2014

(Changes are in italics.)

| | STAGE I: Tumor confined to ovaries | | | | |
|----|---|--|---------------------------------------|---|--|
| | OLD | | | NEW | |
| IA | Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative washings/ascites. | | IA | Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative washings. | |
| IB | Tumor involves both ovaries otherwise like IA. | | IB | Tumor involves both ovaries otherwise like IA. | |
| IC | Tumor involves 1 or both | | IC Tumor limited to 1 or both ovaries | | |
| | ovaries with any of the | | IC1 | Surgical spill | |
| t | following: capsule rupture, tumor on surface, positive washings/ascites. | | IC2 | Capsule rupture before surgery or tumor on ovarian surface. | |
| | | | IC3 | Malignant cells in the ascites or peritoneal washings. | |

| STAGE II: Tumor involves 1 or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer | | | | | |
|---|---|--|-----|--|---|
| | OLD | | | | NEW |
| IIA | Extension and/or implant on uterus and/or Fallopian tubes | | IIA | | Extension and/or implant on uterus and/or Fallopian tubes |
| IIB | Extension to other pelvic intraperitoneal tissues | | IIB | | Extension to other pelvic intraperitoneal tissues |
| IIC | IIA or IIB with positive washings/ascites. | | | | |

^{**}Old stage IIC has been eliminated**

FIGO Ovarian Cancer Staging Effective Jan. 1, 2014

(Changes are in italics.)

| confi | STAGE III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes | | | | |
|-------|---|---|---|--|--|
| OLD | | _ | NEW NEW | | |
| IIIA | Microscopic metastasis beyond the pelvis. | | IIIA (Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the pelvis) | | |
| | | | IIIA1 | Positive retroperitoneal lymph nodes only | |
| | | | | IIIA1(i) Metastasis ≤ 10 mm | |
| | | | | IIIA1(ii) Metastasis > 10 mm | |
| | | | IIIA2 | Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive | |
| IIIB | Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm in greatest dimension. | | IIIB | retroperitoneal lymph nodes Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. | |
| IIIC | Macroscopic, extrapelvic, peritoneal metastasis > 2 cm in greatest dimension and/or regional lymph node metastasis. | | IIIC | Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. | |

| STAG | STAGE IV: Distant metastasis excluding peritoneal metastasis | | | | | |
|------|---|-----|-----|---|--|--|
| OLD | | NEW | | | | |
| IV | Distant metastasis excluding | | IVA | Pleural effusion with positive cytology | | |
| | peritoneal metastasis. Includes hepatic parenchymal metastasis. | | IVB | Hepatic and/or splenic parenchymal metastasis, metastasis to extraabdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) | | |

Other major recommendations are as follows:

- Histologic type including grading should be designated at staging
- Primary site (ovary, Fallopian tube or peritoneum) should be designated where possible
- Tumors that may otherwise qualify for stage I but involved with dense adhesions justify upgrading to stage II if tumor cells are histologically proven to be present in the adhesions